CONTROL ARGININE
ELEVATE YOUR PATIENT
Loargys (pegzilarginase) is the first and only disease-modifying treatment for arginase 1 deficiency (ARG1-D)1
Arginase 1 Deficiency (ARG1‑D) is a debilitating, progressive, inherited metabolic disease associated with the persistent elevation of plasma arginine, which leads to significant morbidity and early mortality.
Loargys indication
Loargys is indicated for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older.2
Loargys is intended for chronic management of patients with ARG1-D in conjunction with individualised disease management such as dietary protein restriction, amino acid supplements and pharmacological treatment including nitrogen scavengers.
Loargys
- Loargys rapidly normalises plasma arginine levels in patients with ARG1-D and reduces toxic arginine-related metabolites1
- Loargys achieves sustained and clinically meaningful improvements in functional outcomes, with a manageable safety profile1
- Loargys has the potential to transform the management of ARG1-D in patients with few clinical options1
- Russo SR et al. Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial eClinicalMedicine.2024;68:102405
- Loargys Summary of Product Characteristics (Nov 2025)